← Leaderboards
Herman F. Staats
Duke University
$31,192,841
Attributed
$31,630,091
Total exposure
24
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$40,088,208 · 25
By mechanism
UC7$11,227,216 · 3
P30$9,764,177 · 3
G20$6,594,615 · 1
R01$4,390,289 · 2
U01$3,790,143 · 1
R21$2,798,697 · 7
Top collaborators
- Soman N Abraham4 shared
Most similar at Duke University
Same institution · by research overlap
- Douglas Brock Cines$21,888,352
- Lubica Rauova$2,618,913
- Genevieve Giny Fouda Amou Ou$19,482,405
- Guido Ferrari$29,050,364
- Thuy Le$9,408,752
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesImmunizationAntigensAdjuvantNoseImmunityImmunoglobulin GOryctolagus CuniculusResourcesResponseVaccinationProgramsGrantPreventImmune ResponseEnsureSerumStructureFundingSafetyUnited States National Institutes Of HealthNeedlesResearch PersonnelArea
Grant awards (59)
Resources and Workforce Development for the Regional Biocontainment Laboratories$2,769,099
UC7 · FY2025 · AI · contact PI
Core-001$1,384,550
UC7 · FY2025 · AI · contact PI
Core-002$1,384,549
UC7 · FY2025 · AI · contact PI
Resources and Workforce Development for the Regional Biocontainment Laboratories$2,806,009
UC7 · FY2024 · AI · contact PI
Developmental Core$648,571
P30 · FY2024 · AI · contact PI
A novel vaccination strategy to curb recUTIs$201,250
R21 · FY2024 · AI
Resources and Workforce Development for the Regional Biocontainment Laboratories$2,883,009
UC7 · FY2023 · AI · contact PI
Developmental Core$996,889
P30 · FY2023 · AI · contact PI
Developing RNA Vaccines to Treat Peanut Hypersensitivity$260,780
R21 · FY2023 · AI · contact PI
A novel vaccination strategy to curb recUTIs$241,500
R21 · FY2023 · AI
Administrative supplement to Duke G20 award$3,264,761
G20 · FY2022 · AI · contact PI
Developmental Core$758,666
P30 · FY2022 · AI · contact PI
Regional Biocontainment Laboratories Facility and Building System Upgrades Support$3,329,854
G20 · FY2021 · AI · contact PI
Developmental Core$1,736,626
P30 · FY2021 · AI · contact PI
Developmental Core$779,565
P30 · FY2020 · AI · contact PI
Developmental Core$626,756
P30 · FY2019 · AI · contact PI
Immunogenicity and Vector Development Core$91,356
P01 · FY2019 · AI · contact PI
Developmental Core$1,038,684
P30 · FY2018 · AI · contact PI
Pregnant rabbits as a model to evaluate the causative role of ZIKV infection in the etiology of congenital malformations$195,569
R21 · FY2018 · AI · contact PI
Immunogenicity and Vector Development Core$194,117
P01 · FY2018 · AI · contact PI
Developmental Core$1,701,355
P30 · FY2017 · AI · contact PI
Pregnant rabbits as a model to evaluate the causative role of ZIKV infection in the etiology of congenital malformations$235,406
R21 · FY2017 · AI · contact PI
Immunogenicity and Vector Development Core$179,670
P01 · FY2017 · AI · contact PI
Developmental Core$876,004
P30 · FY2016 · AI · contact PI
Immunogenicity and Vector Development Core$195,443
P01 · FY2016 · AI · contact PI
Developmental Core$601,061
P30 · FY2015 · AI · contact PI
Mucosal vaccination to protect against HIV-1 infection at mucosal sites$582,882
R01 · FY2015 · AI · contact PI
Immunogenicity and Vector Development Core$341,215
P01 · FY2015 · AI · contact PI
Mucosal vaccination to protect against HIV-1 infection at mucosal sites$607,250
R01 · FY2014 · AI · contact PI
Environmental conditions and their impact on host immunity$75,143
R03 · FY2014 · ES · contact PI
Development of Efficacious and Stable Nasal Vaccine Formulations$670,949
U01 · FY2013 · AI · contact PI
Mucosal vaccination to protect against HIV-1 infection at mucosal sites$651,648
R01 · FY2013 · AI · contact PI
Evaluation of the nasal adjuvant activity of angiotensin peptide Ang-(1-7)$234,930
R21 · FY2013 · AI · contact PI
Environmental conditions and their impact on host immunity$75,952
R03 · FY2013 · ES · contact PI
Development of Efficacious and Stable Nasal Vaccine Formulations$787,200
U01 · FY2012 · AI · contact PI
Mucosal vaccination to protect against HIV-1 infection at mucosal sites$491,944
R01 · FY2012 · AI · contact PI
Evaluation of the nasal adjuvant activity of angiotensin peptide Ang-(1-7)$196,250
R21 · FY2012 · AI · contact PI
Nasal adjuvant to enhance anti-cocaine vaccines$196,250
R21 · FY2012 · DA
Development of Efficacious and Stable Nasal Vaccine Formulations$794,620
U01 · FY2011 · AI · contact PI
Nasal adjuvant to enhance anti-cocaine vaccines$235,500
R21 · FY2011 · DA
EVALUATION OF A PRIME-BOOST VACCINE FOR AEROSOL RICIN EXPOSURE IN NHPS$29,044
P51 · FY2011 · RR · contact PI
Development of Efficacious and Stable Nasal Vaccine Formulations$733,094
U01 · FY2010 · AI · contact PI
Nasal Vaccines: Mode of Action, Composition & Delivery$137,589
R01 · FY2010 · AI · contact PI
Development of Efficacious and Stable Nasal Vaccine Formulations$52,189
U01 · FY2010 · AI · contact PI
Development of Efficacious and Stable Nasal Vaccine Formulations$752,091
U01 · FY2009 · AI · contact PI
Nasal Vaccines: Mode of Action, Composition & Delivery$455,256
R01 · FY2009 · AI · contact PI
Nasal Vaccines: Mode of Action, Composition & Delivery$442,650
R01 · FY2008 · AI · contact PI
DISTRIBUTION AND CLEARANCE OF NASAL VACCINES$6,473
P41 · FY2008 · RR · contact PI
Nasal Vaccines: Mode of Action, Composition & Delivery$493,511
R01 · FY2007 · AI · contact PI
DISTRIBUTION AND CLEARANCE OF NASAL VACCINES$4,985
P41 · FY2007 · RR · contact PI
Nasal Vaccines: Mode of Action, Composition & Delivery$527,559
R01 · FY2006 · AI · contact PI
Mast Cell Activator as Adjuvant for Biodefense Vaccines$300,762
R21 · FY2006 · AI · contact PI
DISTRIBUTION AND CLEARANCE OF NASAL VACCINES$5,126
P41 · FY2006 · RR · contact PI
Mast Cell Activator as Adjuvant for Biodefense Vaccines$308,000
R21 · FY2005 · AI
DISTRIBUTION AND CLEARANCE OF NASAL VACCINES$5,331
P41 · FY2005 · RR
Epitope specificity of vaccine-induced anti-HIV IgG /IgA$192,500
R21 · FY2002 · AI
MUCOSAL IMMUNIZATION WITH HIV/SIV VACCINES$0
P01 · FY2002 · AI
MUCOSAL IMMUNIZATION WITH HIV/SIV VACCINES$0
P01 · FY2001 · AI
MUCOSAL IMMUNIZATION WITH HIV/SIV VACCINES$319,216
P01 · FY2000 · AI